Leerink Partnrs Forecasts Exact Sciences FY2025 Earnings

Exact Sciences Corporation (NASDAQ:EXAS - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for shares of Exact Sciences in a research report issued on Thursday, August 7th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $0.41 per share for the year, up from their previous forecast of $0.28. The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences' Q4 2026 earnings at $0.39 EPS, FY2026 earnings at $1.20 EPS and FY2027 earnings at $2.04 EPS.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.24. The business had revenue of $811.09 million during the quarter, compared to analysts' expectations of $774.43 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%. The company's revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.09) EPS.

Several other brokerages have also recently issued reports on EXAS. Wall Street Zen raised Exact Sciences from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Robert W. Baird upped their price target on Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $46.00 price target (down previously from $54.00) on shares of Exact Sciences in a report on Thursday, August 7th. Piper Sandler reduced their price target on Exact Sciences from $70.00 to $60.00 and set an "overweight" rating for the company in a report on Monday. Finally, BTIG Research reduced their price target on Exact Sciences from $65.00 to $60.00 and set a "buy" rating for the company in a report on Tuesday. Three investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Exact Sciences has an average rating of "Moderate Buy" and a consensus price target of $67.43.

Exact Sciences Stock Performance

Shares of EXAS stock traded down $0.06 on Monday, hitting $44.85. The company had a trading volume of 2,740,900 shares, compared to its average volume of 2,780,224. The firm has a market cap of $8.49 billion, a P/E ratio of -8.26, a price-to-earnings-growth ratio of 4.27 and a beta of 0.93. The company has a 50-day moving average price of $50.78 and a 200-day moving average price of $49.80. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94. Exact Sciences has a twelve month low of $38.81 and a twelve month high of $72.83.

Insiders Place Their Bets

In related news, Director Katherine S. Zanotti sold 3,207 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $53.20, for a total transaction of $170,612.40. Following the sale, the director owned 72,759 shares in the company, valued at $3,870,778.80. This represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Exact Sciences

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Exact Sciences by 3.6% in the first quarter. Vanguard Group Inc. now owns 17,637,674 shares of the medical research company's stock valued at $763,535,000 after purchasing an additional 617,384 shares during the period. Capital World Investors increased its stake in shares of Exact Sciences by 10.7% in the fourth quarter. Capital World Investors now owns 17,537,617 shares of the medical research company's stock valued at $985,439,000 after purchasing an additional 1,696,321 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Exact Sciences by 11.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,403,872 shares of the medical research company's stock valued at $277,225,000 after purchasing an additional 643,631 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in shares of Exact Sciences by 25.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company's stock valued at $239,922,000 after purchasing an additional 876,985 shares during the period. Finally, Mackenzie Financial Corp increased its stake in shares of Exact Sciences by 12.4% in the first quarter. Mackenzie Financial Corp now owns 3,281,639 shares of the medical research company's stock valued at $142,062,000 after purchasing an additional 362,314 shares during the period. Institutional investors and hedge funds own 88.82% of the company's stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.